BMS-986094 (INX-08189) is a prodrug of a guanosine nucleotide analogue which was developed to treat hepatitis C virus but was discontinued during clinical trials due to cardiotoxic effects.
In this poster, we focus on:
- the mechanism of BMS-986094 cardiotoxicity
- the impact of chronic dosing over multiple time points
- evaluation of data from an MEA platform, a cardiac mitochondrial protein biogenesis assay, a calcium flux assay and a cardiac cytotoxicity assay
Read our poster to learn more about our research!